JTT 551 can be used in the research of type 2 diabetes mellitus. JTT 551 is selective a protein tyrosine phosphatase 1B (PTP1B) inhibitor, with Kis of 0.22 μM and 9.3 μM for PTP1B and TCPTP (T-cell protein tyrosine phosphatase), respectively.

PTP1B:0.22 μM , TCPTP:9.3 μM

JTT-551 exhibits low affinity for CD45 protein tyrosine phosphatase (CD45) and leucocyte common antigen-related (LAR) protein tyrosine phosphatase, with dissociation constants (Kis) greater than 30 μM for both. Simultaneously, it enhances insulin-induced deoxyglucose uptake in a dose-dependent manner at concentrations of 10 and 30 μM. Primarily, JTT-551 acts as a selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), demonstrating Kis of 0.22 μM for PTP1B and 9.3 μM for T-cell protein tyrosine phosphatase (TCPTP), thereby indicating its specificity and potential therapeutic utility in modulating insulin sensitivity.

JTT 551 effectively lowers triglyceride (TG) levels at a dosage of 30 mg/kg by Day 7, without impacting insulin and total cholesterol (TC) levels. Additionally, at dosages of 3 mg/kg and 30 mg/kg administered orally (p.o.), this compound demonstrates a dose-dependent reduction in blood glucose levels in db/db mice across multiple time points, specifically on Days 7, 14, and 28.